(ABMD)

業務介紹

艾比歐米德公司從事醫療器械的研究、開發和銷售,以協助或取代衰竭心臟的泵送功能。該公司還為心臟衰竭患者提供全程護理。該公司提供以下產品:

Impella 2.5 - 一種經皮微型心臟泵,具有集成電機和傳感器;
Impella CP - 一種供介入心臟病專科醫生在導管實驗室使用,以及供心臟外科醫生在心臟手術室使用的設備;
Impella 5.0、Impella LD 和 Impella 5.5 - 主要用於心臟手術室的經皮微型心臟泵,具有集成電機和傳感器;
Impella RP - 一種基於導管的軸流泵;
Impella SmartAssist 平台 - 包括光學傳感器技術,用於改善泵的定位,並使用算法在脫離過程中改善原發心臟評估;
Impella Connect - 一種基於雲端的技術,可讓醫生和醫院工作人員安全遠程查看自動 Impella 控制器;
OXY-1 System - 一種便攜式外部呼吸輔助設備。

此外,該公司正在開發 Impella ECP(一種流量大於每分鐘3升的泵)、Impella XR Sheath(一種可擴張和回彈的鞘管,允許小口徑進出和閉合)、Impella BTR(一種經皮微型心臟泵,具有集成電機和傳感器)以及 preCARDIA(一種導管安裝的上腔靜脈治療系統,旨在快速治療急性失代償性心力衰竭)。

艾比歐米德公司通過直銷和臨床支持人員在德國、法國、美國、日本、歐洲、加拿大、拉丁美洲、亞太地區和中東銷售其產品。該公司成立於1981年,總部位於馬薩諸塞州的丹佛斯。截至2022年12月22日,艾比歐米德公司成為強生公司的子公司。



Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

公司網址

https://www.abiomed.com